Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 8Recruiting 6Unknown 2Terminated 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 1Nausea 1Gynecologic Cancer 1

Interventions

Cisplatin 62Carboplatin 52Paclitaxel 49Radiotherapy 47Docetaxel 42Gemcitabine 38Cyclophosphamide 36Rituximab 33Capecitabine 28Fluorouracil 27Dexamethasone 27Doxorubicin 26Prednisone 21Bevacizumab 20Pemetrexed 19Oxaliplatin 18Leucovorin 18pembrolizumab 17Vincristine 17Etoposide 17Cytarabine 15Imatinib Mesylate 14Drug Therapy 14Irinotecan 13Filgrastim 13Zoledronic Acid 12Trastuzumab 12Radiosurgery 12Erlotinib Hydrochloride 12Goserelin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Terminated × Olanzapine × Clear all
NCT04503668 2025-06-18

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

University of Michigan Rogel Cancer Center

Phase 3 Terminated
62 enrolled 16 charts
Gynecologic

Gynecologic Cancer

NCT00124930 2012-01-19

Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

AHS Cancer Control Alberta

Phase 3 Terminated
80 enrolled

Nausea, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡